Amundi
CRL icon

Amundi’s Charles River Laboratories CRL Stock Holding History

Amundi’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.5M Sell
412,402
-360,913
-47% -$64.3M 0.02% 480
2026
Q1 		$133M Buy
773,315
+492,301
+175% +$91.3M 0.04% 382
2025
Q4 		$56.1M Sell
281,014
-29,160
-9% -$5.29M 0.02% 613
2025
Q3 		$54.3M Buy
310,174
+83,917
+37% +$13.3M 0.02% 542
2025
Q2 		$35.6M Buy
226,257
+209,910
+1,284% +$28M 0.01% 615
2025
Q1 		$2.3M Sell
16,347
-53,919
-77% -$9.04M ﹤0.01% 1116
2024
Q4 		$13.2M Buy
70,266
+16,599
+31% +$3.2M ﹤0.01% 799
2024
Q3 		$10M Sell
53,667
-4,643
-8% -$965K ﹤0.01% 847
2024
Q2 		$11.7M Buy
58,310
+608
+1% +$138K ﹤0.01% 801
2024
Q1 		$13.1M Sell
57,702
-12,888
-18% -$3.08M 0.01% 781
2023
Q4 		$15.2M Buy
70,590
+25,896
+58% +$5.09M 0.01% 762
2023
Q3 		$8.54M Sell
44,694
-22,543
-34% -$4.63M ﹤0.01% 868
2023
Q2 		$14M Sell
67,237
-109,173
-62% -$21.7M 0.01% 770
2023
Q1 		$34.5M Buy
176,410
+63,983
+57% +$14.5M 0.02% 593
2022
Q4 		$27.8M Sell
112,427
-25,753
-19% -$5.62M 0.02% 632
2022
Q3 		$29.8M Sell
138,180
-55,123
-29% -$11.9M 0.02% 613
2022
Q2 		$40.7M Buy
193,303
+49,086
+34% +$12M 0.03% 483
2022
Q1 		$43.6M Buy
144,217
+4,915
+4% +$1.52M 0.03% 493
2021
Q4 		$49M Sell
139,302
-51,448
-27% -$20M 0.03% 481
2021
Q3 		$78.7M Buy
190,750
+35,082
+23% +$14.6M 0.06% 343
2021
Q2 		$57.6M Buy
+155,668
New +$52M 0.04% 409

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Amundi's CRL Position: Q2 2026 in Review

Amundi reduced its Charles River Laboratories (CRL) stake by 47% in Q2 2026, selling an estimated $64.3M and leaving 412,402 shares worth $93.5M. The position accounts for 0.02% of the portfolio, ranked #480.

Amundi first reported a position in CRL in Q2 2021 and has held it in 21 quarters since. The position peaked at $133M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Amundi held 412,402 shares of Charles River Laboratories worth $93.5M as of Q2 2026.
  • Amundi sold 360,913 Charles River Laboratories shares in Q2 2026, an estimated $64.3M.
  • Charles River Laboratories made up 0.02% of Amundi's portfolio in Q2 2026, its #480 holding.
  • Amundi first reported a position in Charles River Laboratories in Q2 2021 and has held it in 21 quarters since.
  • Amundi's Charles River Laboratories position peaked at $133M in Q1 2026.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.